Bio‑Rad EVP Barry James Receives Award, Sells Shares for Taxes

What Happened
Barry James, Executive Vice President and President, LSG of Bio‑Rad Laboratories (BIO), had restricted stock units (RSUs) convert to 425 shares on September 1, 2026. Of those vested shares, 154 were withheld/used to satisfy tax withholding obligations (payment shown as 154 shares at $380.96 each = $58,668). The underlying RSU conversions are reported as derivative exercises/conversions.

Key Details

• Transaction date: 2026-09-01; filing date: 2026-09-03 (appears timely — within the typical 2-business-day window).
• Reported entries: 425 shares acquired via conversion of RSUs (@ $0.00); 154 shares disposed/withheld to satisfy tax liability at $380.96/share (≈ $58,668); two separate conversion lines of 174 and 251 shares (these correspond to the two grant tranches).
• Net effect: roughly 425 shares vested and ~154 shares withheld for taxes, yielding a net increase of about 271 shares to James’s holdings (filing does not state total shares held after the transaction).
• Footnotes: each RSU equals one share (F2); the reported vesting reflects grants made on 9/1/2022 (694 RSUs) and 9/1/2023 (1,002 RSUs) that vest in four equal annual installments (F3, F4). The withholding is a routine tax payment (F1).

Context
These transactions are compensation-related (RSU vesting and tax withholding), not open-market purchases or discretionary sales. Tax‑withholding disposals are common when equity awards vest and generally reflect routine payroll tax settlement rather than a signal of intent to liquidate holdings.